Lung cancer drug combo study halted early
Disease control
Terminated
This study tested a new drug called bemcentinib combined with standard chemotherapy and immunotherapy for people with advanced non-squamous non-small cell lung cancer. The goal was to see if the combination was safe and could shrink tumors, especially in patients with a specific …
Phase: PHASE1, PHASE2 • Sponsor: BerGenBio ASA • Aim: Disease control
Last updated May 22, 2026 13:52 UTC